Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 141, Issue 1, 2008, Pages 64-69

  Engel, Jörg B ^a   Honig, Arnd ^a   Schönhals, Tanja ^a   Weidler, Claudia ^a   Häusler, Sebastian ^a   Krockenberger, Mathias ^a   Grunewald, Thomas G ^b   Dombrowski, Yvonne ^a   Rieger, Lorenz ^a   Dietl, Johannes ^a   Wischhusen, Jörg ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

AKT inhibition; Endometrial cancer; Perifosine; Platin; Programmed cell death

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CISPLATIN; PERIFOSINE; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CELL DEATH; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA CONTENT; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; ENDOMETRIUM CANCER; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO SELECTION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 54849405505     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2008.06.007     Document Type: Article

References (35)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics 2007. CA Cancer J Clin 57 1 (2007) 43-66
2. Creasman W.T., Odicino F., Maisonneuve P., et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 6 1 (2001) 47-86
3. Aalders J.G., Abeler V., and Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol 17 1 (1984) 85-103
4. Tashiro H., Blazes M.S., Wu R., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57 18 (1997) 3935-3940
5. Cheng J.Q., Lindsley C.W., Cheng G.Z., Yang H., and Nicosia S.V. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24 50 (2005) 7482-7492
6. Chow L.M., and Baker S.J. PTEN function in normal and neoplastic growth. Cancer Lett 241 2 (2006) 184-196
7. Kanamori Y., Kigawa J., Itamochi H., et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 7 4 (2001) 892-895
8. Terakawa N., Kanamori Y., and Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 10 2 (2003) 203-208
9. Kondapaka S.B., Singh S.S., Dasmahapatra G.P., Sausville E.A., and Roy K.K. Perifosine a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2 11 (2003) 1093-1103
10. Momota H., Nerio E., and Holland E.C. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 65 16 (2005) 7429-7435
11. Ruiter G.A., Zerp S.F., Bartelink H., van Blitterswijk W.J., and Verheij M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 14 2 (2003) 167-173
12. Elrod H.A., Lin Y.D., Yue P., et al. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 6 7 (2007) 2029-2038
13. Hideshima T., Catley L., Yasui H., et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107 10 (2006) 4053-4062
14. Leighl N.B., Dent S., Clemons M., et al. A phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat (2007)
15. Argiris A., Cohen E., Karrison T., et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 5 7 (2006) 766-770
16. Posadas E.M., Gulley J., Arlen P.M., et al. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 4 10 (2005) 1133-1137
17. Marsh Rde W., Rocha Lima C.M., Levy D.E., Mitchell E.P., Rowland Jr. K.M., and Benson III A.B. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol 30 1 (2007) 26-31
18. Bailey H.H., Mahoney M.R., Ettinger D.S., et al. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer 107 10 (2006) 2462-2467
19. Weller M., Rieger J., Grimmel C., et al. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int J Cancer 79 6 (1998) 640-644
20. Jin X., Gossett D.R., Wang S., et al. Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. Br J Cancer 91 10 (2004) 1808-1812
21. Albitar L., Pickett G., Morgan M., Davies S., and Leslie K.K. Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells. Gynecol Oncol 106 1 (2007) 52-64
22. Wan X., Li J., Xie X., and Lu W. PTEN augments doxorubicin-induced apoptosis in PTEN-null Ishikawa cells. Int J Gynecol Cancer 17 4 (2007) 808-812
23. Vink S.R., Schellens J.H., van Blitterswijk W.J., and Verheij M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs 23 4 (2005) 279-286
24. Vink S.R., Lagerwerf S., Mesman E., et al. Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. Clin Cancer Res 12 5 (2006) 1615-1622
25. Patel V., Lahusen T., Sy T., Sausville E.A., Gutkind J.S., and Senderowicz A.M. Perifosine a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res 62 5 (2002) 1401-1409
26. Ernst D.S., Eisenhauer E., Wainman N., et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 23 6 (2005) 569-575
27. Van Ummersen L., Binger K., Volkman J., et al. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10 22 (2004) 7450-7456
28. Crul M., Rosing H., de Klerk G.J., et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 38 12 (2002) 1615-1621
29. Knowling M., Blackstein M., Tozer R., et al. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 24 5 (2006) 435-439
30. Cully M., You H., Levine A.J., and Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6 3 (2006) 184-192
31. Rahmani M., Reese E., Dai Y., et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 65 6 (2005) 2422-2432
32. Naumann U., Wischhusen J., Weit S., et al. Alkylphosphocholine-induced glioma cell death is BCL-X(L)-sensitive, caspase-independent and characterized by massive cytoplasmic vacuole formation. Cell Death Differ 11 12 (2004) 1326-1341
33. Naumann U., Kugler S., Wolburg H., et al. Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. Cancer Res 61 15 (2001) 5833-5842
34. Lee M.W., Kim D.S., Min N.Y., and Kim H.T. Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin. Int J Cancer 122 10 (2008) 2380-2384
35. Yang X., Fraser M., Moll U.M., Basak A., and Tsang B.K. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 66 6 (2006) 3126-3136